RE:RE:RE:RE:RE:China Daily ArticleWhen you are talking a takeover price of $1.5-2.0B, the 'optics' can never look bad, trust me. I think it's also important to understand that Vantive has been studying endotoxins for a long while now, as their research and develpment of AN69 (Oxiris) has progressed. It's not like nobody but Spectral has believed in the endotoxin removal theory, it's just that Spectrals product PMX, removes it the best.
Even if Vantive/CG didn't actually get to see the crude data so far in the Tigris trial, they would still understand and have a strong conviction in the endo-removal theory because of all their internal data from Oxiris. That being said, should Vantive with it's newfound deep pockets owner, decide to make a play on Spectral before the topline is officially released, all they would have to do is approach with a Bona Fide takeover interest, sign NDA's between each other, probably share crude data, and then talk brass tacks about price. Everything is always for sale at any given moment, so long as it's at the right price to make it happen.